

# Steven G Terra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5179381/publications.pdf>

Version: 2024-02-01

36  
papers

1,425  
citations

430442

18  
h-index

344852

36  
g-index

36  
all docs

36  
docs citations

36  
times ranked

945  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and baseline characteristics of the eValuation of ERtugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal, 2018, 206, 11-23.	1.2	171
2	Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (<scp>VERTIS MET</scp>). Diabetes, Obesity and Metabolism, 2018, 20, 520-529.	2.2	136
3	Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The <scp>VERTIS FACTORIAL</scp> randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1111-1120.	2.2	121
4	Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The <scp>VERTIS SITA2</scp> placebo-controlled randomized study. Diabetes, Obesity and Metabolism, 2018, 20, 530-540.	2.2	121
5	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes, Obesity and Metabolism, 2017, 19, 721-728.	2.2	113
6	Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. Diabetes Therapy, 2018, 9, 49-66.	1.2	99
7	Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study. Diabetes Therapy, 2018, 9, 193-207.	1.2	86
8	Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, Obesity and Metabolism, 2018, 20, 1453-1460.	2.2	70
9	Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Therapy, 2018, 9, 253-268.	1.2	68
10	Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes, Obesity and Metabolism, 2019, 21, 1027-1036.	2.2	48
11	Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes, Obesity and Metabolism, 2019, 21, 1474-1482.	2.2	38
12	Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia, 2020, 63, 1128-1140.	2.9	33
13	Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin. Clinical and Translational Science, 2018, 11, 405-411.	1.5	32
14	Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Current Medical Research and Opinion, 2019, 35, 1335-1343.	0.9	32
15	Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clinical Pharmacokinetics, 2020, 59, 949-965.	1.6	32
16	Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects. Clinical Pharmacology in Drug Development, 2019, 8, 314-325.	0.8	23
17	Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies. Diabetes and Vascular Disease Research, 2019, 16, 415-423.	0.9	21
18	Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin. Clinical Pharmacology in Drug Development, 2019, 8, 619-627.	0.8	21

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment. <i>Clinical Therapeutics</i> , 2018, 40, 1701-1710.	1.1	17
20	A Phase 1, Randomized, Placebo- and Active- Controlled Crossover Study to Determine the Effect of Single-Dose Ertugliflozin on QTc Interval in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 513-523.	0.8	15
21	Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. <i>Cardiovascular Diabetology</i> , 2019, 18, 59.	2.7	14
22	Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. <i>Diabetes Therapy</i> , 2020, 11, 1347-1367.	1.2	14
23	A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 57, 207-216.	0.3	14
24	Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects. <i>Clinical Therapeutics</i> , 2018, 40, 1538-1547.	1.1	13
25	Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2276-2286.	2.2	12
26	Efficacy and Safety of a Potent and Selective Peroxisome Proliferator Activated Receptor Alpha Agonist in Subjects With Dyslipidemia and Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 102, 434-439.	0.7	11
27	Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. <i>Diabetes Therapy</i> , 2020, 11, 1849-1860.	1.2	9
28	Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus. <i>Obesity</i> , 2020, 28, 724-732.	1.5	9
29	Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 574-582.	2.2	8
30	Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2020, 36, 1277-1284.	0.9	6
31	Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 884-894.	0.8	4
32	Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 50-61.	0.8	4
33	Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2020, 36, 1097-1106.	0.9	3
34	A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin. <i>Diabetes</i> , 2018, 67, .	0.3	3
35	Evaluation of Fractures, Bone Mineral Density (BMD), and Bone Biomarkers in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. <i>Diabetes</i> , 2018, 67, 1145-P.	0.3	3
36	Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM). <i>Diabetes</i> , 2018, 67, .	0.3	1